News and Announcements
Actinogen Medical Successfully Treats First Australian & US Patients & Reports Cash of $3.9m
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX:ACW) has recently provided a summary of its progress over the quarter ended June 30, 2017.
KEY TAKEAWAYS:
- The company achieved significant milestones with Actinogen’s Alzheimer’s disease trial, with the successful treatment of the first Australian and US patients.
- Represents a landmark in the global search for a new effective treatment.
- Additional trial sites in Australia, the US and the UK are expected soon commence enrolling patients, with the final patient planned to be enrolled by Q4 2018.
- Cash at 30th June 2017 of $3.989million.
The Company remains focused on ensuring the trial progresses as planned and looks forward to updating the market on its progress over the near medium term.
“We are delighted to have had such a strong momentum behind XanADu, a ground-breaking trial that shows Australia is leading the way in developing this promising new treatment for Alzheimer’s disease,” said Dr Bill Ketelbey, CEO of Actinogen Medical.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
